LHC utilizes an integrative biology and translational research strategy to investigate: molecular mechanisms of carcinogenesis including human liver, lung and colon carcinogenesis, hypoxia-driven carcinogenesis and tumor progression; molecular epidemiology of human cancer including breast, prostate, lung and colon. And cancer biomarkers of diagnosis, prognosis, and therapeutic outcome of lung, colon and prostate cancer.

Our continuing research projects utilize an integrative biology and translational strategy that addresses facets of the NCI strategic objectives: (a) Understand the causes and mechanisms of cancer; (b) Improve early detection and diagnosis; (c) Understand the factors that influence cancer outcomes; and (d) Overcome cancer health disparities. (The NCI Strategic Objectives; the Nation's Investment in Cancer Research, FY2009) As described in the overview of LHC, our strategy and strength is to conduct laboratory-epidemiological investigations and to mentor young investigators.

LHC research also has a strong translational component, e.g., development of diagnostic and prognostic biomarkers, and therapeutic targets of liver, prostate and lung cancer.